Menu Menu


AZN Financials       Clear


AZN        0000901832    
Filing Date Form Type Description Document
2018-05-21 6-K AZ REGULATORY SUBMISSION IN JAPAN FOR FORXIGA View Document
2018-05-21 6-K US FDA APPROVES LOKELMA FOR ADULT HYPERKALAEMIA View Document
2018-05-18 6-K RESULT OF AGM View Document
2018-05-18 6-K AZN: Q1 2018 RESULTS View Document
2018-05-11 6-K ASTRAZENECA UPDATE ON FASENRA PIII TRIAL IN COPD View Document
2018-05-08 6-K EMA APPROVES LYNPARZA: MAINTENANCE OVARIAN CANCER View Document
2018-05-07 6-K AZ AND LUYE PHARMA ENTER AGREEMENT FOR SEROQUEL View Document
2018-05-04 6-K DIRECTOR DECLARATION View Document
2018-05-01 6-K TOTAL VOTING RIGHTS View Document
2018-04-27 6-K AZ: POSITIVE CHMP FOR TAGRISSO FIRST-LINE NSCLC View Document
2018-04-24 6-K ASTRAZENECA:HIGH LEVEL RESULTS OF THE ARCTIC TRIAL View Document
2018-04-19 6-K FDA APPROVES TAGRISSO FOR 1ST-LINE USE IN NSCLC View Document
2018-04-13 6-K 6-K View Document
2018-04-13 6-K NOTICE OF AGM View Document
2018-04-05 6-K DIRECTORATE CHANGE View Document
2018-04-03 6-K TOTAL VOTING RIGHTS View Document
2018-04-03 6-K FDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIA View Document
2018-04-03 6-K AZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EU View Document
2018-03-28 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2018-03-26 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2018-03-22 6-K LOKELMA APPROVED IN THE EU View Document
2018-03-12 6-K ASTRAZENECA UPDATES MYSTIC TRIAL TIMELINE View Document
2018-03-07 6-K FILING OF FORM 20-F WITH SEC View Document
2018-03-06 IRANNOTICE IRANNOTICE View Document
2018-03-06 20-F 20-F View Document
2018-03-06 6-K ANNUAL FINANCIAL REPORT View Document
2018-03-01 6-K TOTAL VOTING RIGHTS View Document
2018-02-23 6-K LYNPARZA CHMP FOR OVARIAN CANCER MAINTAINANCE View Document
2018-02-20 6-K ASTRAZENECA'S IMFINZI APPROVED FOR STAGE III NSCLC View Document
2018-02-15 6-K SELUMETINIB IN NF1 GETS FDA ORPHAN DRUG STATUS View Document
2018-02-08 SC 13G SCHEDULE 13G View Document
2018-02-08 SC 13G/A SEC SCHEDULE 13G View Document
2018-02-05 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2018-02-02 6-K AZN: FULL-YEAR 2017 RESULTS View Document
2018-02-01 6-K TOTAL VOTING RIGHTS View Document
2018-01-30 SC 13G/A View Document
2018-01-26 6-K/A AZ REPORTS PHASE III RESULTS FOR PT010 IN COPD View Document
2018-01-26 6-K AZ REPORTS PHASE III RESULTS FOR PT010 IN COPD View Document
2018-01-19 6-K ASTRAZENECA'S FASENRA RECEIVES APPROVAL IN JAPAN View Document
2018-01-19 6-K LYNPARZA APPROVED IN JAPAN FOR OVARIAN CANCER View Document
2018-01-12 6-K FDA APPROVES LYNPARZA FOR METASTATIC BREAST CANCER View Document
2018-01-10 6-K ASTRAZENECA'S FASENRA APPROVED IN THE EU View Document
2018-01-02 6-K TOTAL VOTING RIGHTS View Document
2017-12-28 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2017-12-18 6-K FDA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC View Document
2017-12-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2017-12-11 SC 13D/A SC 13D/A View Document
2017-12-05 4 FORM 4 SUBMISSION View Document
2017-12-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2017-12-01 6-K TOTAL VOTING RIGHTS View Document
2017-11-28 6-K EMA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC View Document
2017-11-27 6-K AZ SUBMITS TAGRISSO IN JAPAN FOR 1ST-LINE NSCLC View Document
2017-11-15 6-K AZ FASENRA RECEIVES FDA APPROVAL FOR SEVERE ASTHMA View Document
2017-11-13 6-K BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMA View Document
2017-11-09 6-K AZN: YEAR-TO-DATE AND Q3 2017 RESULTS ANNOUNCEMENT View Document
2017-11-01 6-K TOTAL VOTING RIGHTS View Document
2017-11-01 6-K ASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL View Document
2017-11-01 6-K ASTRAZENECA TRALOKINUMAB UPDATE IN SEVERE ASTHMA View Document
2017-10-31 6-K US FDA APPROVES ASTRAZENECA'S CALQUENCE FOR MCL View Document
2017-10-23 6-K US FDA APPROVES BYDUREON BCISE FOR TYPE-2 DIABETES View Document
2017-10-23 6-K AZ AND MSD RAPIDLY ADVANCE LYNPARZA IN JAPAN View Document
2017-10-18 6-K FDA PRIORITY REVIEW FOR LYNPARZA IN BREAST CANCER View Document
2017-10-17 6-K FDA ACCEPTS SBLA FILE FOR IMFINZI; PRIORITY REVIEW View Document
2017-10-10 6-K FDA GRANTS TAGRISSO BTD FOR 1ST-LINE EGFR NSCLC View Document
2017-10-02 6-K TOTAL VOTING RIGHTS View Document
2017-09-26 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2017-09-15 25-NSE View Document
2017-09-14 6-K ASPEN ACQUIRES REMAINING RIGHTS TO AZ ANAESTHETICS View Document
2017-09-11 6-K IMFINZI SUPERIOR PFS IN STAGE III LUNG CANCER View Document
2017-09-11 6-K TAGRISSO POTENTIAL STANDARD OF CARE IN LUNG CANCER View Document
2017-09-07 6-K CELGENE AND AZ UPDATE ON FUSION TRIAL PROGRAMME View Document
2017-09-07 6-K AZ DUAKLIR IMPROVES LUNG FUNCTION IN COPD PATIENTS View Document
2017-09-07 6-K AZ TEZEPELUMAB CUTS EXACERBATIONS IN SEVERE ASTHMA View Document
2017-09-05 6-K DIRECTORATE CHANGE View Document
2017-09-01 6-K TOTAL VOTING RIGHTS View Document
2017-08-17 6-K LYNPARZA GETS BROAD FDA APPROVAL IN OVARIAN CANCER View Document
2017-08-16 6-K DIRECTORATE CHANGE View Document
2017-08-14 6-K HOLDING(S) IN COMPANY View Document
2017-08-10 6-K PUBLICATION OF A PROSPECTUS View Document
2017-08-02 6-K AZ ACALABRUTINIB SUBMISSION ACCEPTED BY US FDA View Document
2017-08-01 6-K TOTAL VOTING RIGHTS View Document
2017-08-01 6-K BTD FOR AZS ACALABRUTINIB IN MANTLE CELL LYMPHOMA View Document
2017-07-31 6-K IMFINZI GRANTED BTD BY US FDA FOR STAGE III NSCLC View Document
2017-07-28 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2017-07-27 6-K TAGRISSO SIGNIFICANTLY IMPROVES FLAURA View Document
2017-07-27 6-K AZ REPORTS INITIAL RESULTS FROM MYSTIC LUNG TRIAL View Document
2017-07-27 6-K AZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEAL View Document
2017-07-27 6-K ASTRAZENECA PLC - H1 2017 RESULTS View Document
2017-07-26 6-K FASLODEX RECEIVES EU APPROVAL FOR 1L BREAST CANCER View Document
2017-07-21 6-K HOLDING(S) IN COMPANY View Document
2017-07-03 6-K TOTAL VOTING RIGHTS View Document
2017-07-03 6-K AZ COMPLETES SELOKEN AGREEMENT WITH RECORDATI View Document
2017-07-03 6-K AZ COMPLETES ZOMIG DIVESTMENT WITH GRUNENTHAL View Document
2017-06-29 11-K AUTO-GENERATED PAPER DOCUMENT View Document
2017-06-23 6-K FASLODEX CHMP POSITIVE OPINION IN 1L BREAST CANCER View Document
2017-06-14 CERTNYS AUTO-GENERATED PAPER DOCUMENT View Document
2017-06-12 8-A12B FORM 8-A12B View Document
2017-06-12 6-K FORM 6-K View Document
2017-06-07 424B2 FORM 424B2 View Document
2017-06-07 6-K AZ AGREEMENT WITH GRUNENTHAL FOR RIGHTS TO ZOMIG View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.



We can also help with your taxes.

Formal Tax

www.formal.tax





(402) 804-8293


Formal Financial App
Google Play - Apple Store

created using: Admin Canvas